LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 3, 2007, Pages 309-317

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Sader, Helio S ^a,c   Ross, James E ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gram positives; LEADER; Linezolid; Resistance; Surveillance

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HEALTH CENTER; HEALTH PROGRAM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; SENTINEL SURVEILLANCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED STATES;

EID: 35548957431     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.06.004     Document Type: Article

References (34)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox annual appraisal of potency and spectrum (ZAAPS) program. Int. J. Antimicrob. Agents 26 (2005) 13-21
2. Antony S.J., Bitter K.M., Moreland T., Raudales F., and Diaz-Luna H. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms. Clin. Infect. Dis. 29 (1999) 1341-1342
3. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36 (2003) 159-168
4. Bourgeois-Nicolaos N., Massias L., Couson B., Butel M.J., Andremont A., and Doucet-Populaire F. Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J. Infect. Dis. 195 (2007) 1480-1488
5. Chen D.K., McGeer A., de Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341 (1999) 233-239
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard. M7-A7. 7th ed. (2006), CLSI, Wayne, PA
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard. M2-A9. 9th ed. (2006), CLSI, Wayne, PA
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement. M100-S17 (2007), CLSI, Wayne, PA
9. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
10. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49 (2005) 5024-5032
11. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn. Microbiol. Infect. Dis. 55 (2006) 129-133
12. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. ZAAPS program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect. Dis. (2007) (in press)
13. Jones R.N., Ross J.E., Fritsche T.R., and Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® annual appraisal of potency and spectrum (ZAAPS) program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57 (2006) 279-287
14. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30 (2004) 388-394
15. Livermore D.M. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51 Suppl 2 (2003) ii9-ii16
16. McNeil S.A., Clark N.M., Chandrasekar P.H., and Kauffman C.A. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clin. Infect. Dis. 30 (2000) 403-404
17. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39 (2004) 1010-1015
18. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138 (2003) 135-142
19. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43 (2002) 65-73
20. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
21. Mylona E., Fanourgiakis P., Vryonis E., Golfinopoulou S., Skoutelis A., Platsouka E., and Chatzis N. Linezolid-based therapy in Staphylococcus epidermidis endocarditis. Int. J. Antimicrob. Agents 29 (2007) 597-598
22. Noskin G.A., Siddiqui F., Stosor V., Kruzynski J., and Peterson L.R. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin. Infect. Dis. 28 (1999) 689-690
23. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
24. Raad I.I., Hanna H.A., Hachem R.Y., Dvorak T., Arbuckle R.B., Chaiban G., and Rice L.B. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob. Agents Chemother. 48 (2004) 3583-3585
25. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., and Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52 (2005) 53-58
26. Ross J.E., Fritsche T.R., Sader H.S., and Jones R.N. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 29 (2007) 295-301
27. Rubinstein E., Cammarata S., Oliphant T., and Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32 (2001) 402-412
28. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34 (2002) 1481-1490
29. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall S.E., Todd W.M., and Hafkin B. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44 (2000) 3408-3413
30. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (2005) 2260-2266
31. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25 (2003) 980-992
32. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
33. Zeana C., Kubin C.J., Della-Latta P., and Hammer S.M. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin. Infect. Dis. 33 (2001) 477-482
34. Zyvox Package Insert. Pfizer. Available at (2004). http://www.pfizer.com/pfizer/download/uspi_zyvox.pdf